ALX Oncology

We are pleased to announce that updated results from the randomized Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. #GI25 Details can be found here: https://bit.ly/41HKTlg

Join us next week for our virtual company event! Our CEO, Jason Lettmann, and CMO, Alan Sandler, MD, will be joined by leading breast cancer medical oncologist, Dr. Alberto J. Montero, University Hospitals, to discuss the first data from a Phase 1b/2 clinical trial evaluating the company’s investigational CD47-blocker evorpacept in combination with zanidatamab in heavily pretreated patients with metastatic breast cancer. View today's press release and learn how to register: https://bit.ly/41vOwLd

We look forward to the presentation of the first data from a Phase 1b/2 trial evaluating our lead investigational therapy, evorpacept, in combination with zanidatamab in a poster spotlight presentation this Thursday at #SABCS2024.    These data provide valuable insights and add to the growing body of evidence supporting continued advancement of the robust evorpacept clinical program across a variety of cancers. Read more about the data in today's press release: https://bit.ly/3ZuvhPl

ALX Oncology will attend the Piper Sandler 36th Annual Healthcare Conference in New York City this month. Make sure to tune into the fireside chat with our CEO, Jason Lettmann. Registration details can be found here: https://bit.ly/3OtBZ34

We are pleased to welcome Alan Sandler, MD, to our executive leadership team as Chief Medical Officer. “Dr. Sandler’s breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives. He is the ideal leader to advance the clinical development of evorpacept, our investigational lead compound, into late-stage clinical trials. We are thrilled to have him join our accomplished leadership team as we look towards 2025, which will be a transformational year for the company.” - Jason Lettmann, CEO of ALX Oncology Read more about Alan here: https://bit.ly/4frf98a

We’ve announced Q3 2024 financial results and recent business developments. "We made substantial clinical progress during the third quarter, most notably announcing topline data from our ASPEN-06 Phase 2 trial in which our lead candidate evorpacept became the first and only CD47-blocking agent to show a durable clinical benefit and a well-tolerated safety profile in a prospective randomized clinical trial. These results provided further validation for evorpacept’s novel mechanism of action and our robust evorpacept clinical program. We anticipate achieving several additional clinical milestones in the near-term that could advance evorpacept towards being a best-in-class, combinable therapeutic across a wide range of cancer types." - Jason Lettmann, CEO of ALX Oncology Read more: https://bit.ly/4fhuPdQ

ALX Oncology will attend two investment conferences this month, traveling from UBS Healthcare in California to Jefferies Healthcare in London. Be sure to tune into the fireside chats with our CEO, Jason Lettmann. Registration details can be found here: https://bit.ly/40xegpJ

We are pleased to announce that results from the Phase 1b/2 trial of evorpacept in combination with zanidatamab have been accepted for presentation at the San Antonio Breast Cancer Symposium in December. #SABCS2024 The poster spotlight presentation will highlight new data on our lead asset evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers. Details can be found here: https://bit.ly/3YNoQHZ

Tomorrow at the Biotechnology Innovation Organization Investor Forum, a panel of industry experts including our Chief Financial Officer Pete Garcia will discuss the current IPO landscape and how biotech companies can best position themselves for success in today’s dynamic market. Don’t miss it if you’re attending #BIF2024! View the agenda here: https://lnkd.in/dT3zhgkY

Attending the Hanson Wade Group 6th Annual Macrophage-Directed Therapies Summit in Boston this week? Tomorrow hear from our President and Chief Scientific Officer, Jaume Pons, on how combining therapies to enhance macrophage-directed investigational treatment could offer a promising avenue in oncology. 🔍 Key Highlights: Strategizing the logical design of a combination therapy to enhance the efficacy of your macrophage-directed therapy. Weighing up the benefits and drawbacks of combination therapies to grasp their appeal. Reviewing the costs and other limiting factors associated with combination therapies. #HealthcareInnovation #CombinationTherapy #MacrophageResearch https://lnkd.in/e6rE5mX7